Glioblastoma (GB) is the highest grade and most common form of primary adult brain tumors, characterized by a highly invasive cell population. GB tumors develop treatment resistance and ultimately recur; the median survival is nearly fifteen months and importantly, the invading cell population is attributed with having a decreased sensitivity to therapeutics. Thus, there remains a necessity to identify the genetic and signaling mechanisms that promote tumor spread and therapeutic resistance in order to develop new targeted treatment strategies to combat this rapidly progressive disease. TWEAK-Fn14 ligand-receptor signaling is one mechanism in GB that promotes cell invasiveness and survival, and is dependent upon the activity of multiple Rho GTPases including Rac1. Here, we show that Cdc42 is essential in Fn14-mediated Rac1 activation. We identified two guanine nucleotide exchange factors (GEFs), Ect2 and Trio, involved in the TWEAK-induced activation of Cdc42 and Rac1, respectively, as well as in the subsequent TWEAK-Fn14 directed glioma cell migration and invasion. In addition, we characterized the role of SGEF in promoting Fn14-induced Rac1 activation. SGEF, a RhoG-specific GEF, is overexpressed in GB tumors and promotes TWEAK-Fn14-mediated glioma invasion. Moreover, we characterized the correlation between SGEF expression and TMZ resistance, and defined a role for SGEF in promoting the survival of glioma cells. SGEF mRNA and protein expression are regulated by the TWEAK-Fn14 signaling axis in an NF-kB dependent manner and inhibition of SGEF expression sensitizes glioma cells to TMZ treatment. Lastly, gene expression analysis of SGEF depleted GB cells revealed altered expression of a network of DNA repair and survival genes. Thus TWEAK-Fn14 signaling through the GEF-Rho GTPase systems which include the Ect2, Trio, and SGEF activation of Cdc42 and/or Rac1 presents a pathway of attractive drug targets in glioma therapy, and SGEF signaling represents a novel target in the setting of TMZ refractory, invasive GB cells.

Tissue factor (TF) is a cell-associated receptor for coagulation factor VIIa (FVIIa) that initiates the coagulation cascade and transmits intracellular signals through protease activated receptors (PARs). This thesis documents for the first time that in human glioma cells (U373) oncogenic epidermal growth factor receptor (EGFRvIII) simultaneously upregulates the expression of several elements of the TF pathway (TF, FVIIa, PAR-1 and PAR-2). In the absence of EGFRvIII, TF triggers tumor formation, albeit with a long latency, while treatment of glioma cells with FVIIa activates MAPK phosphorylation and stimulates the expression of angiogenic factors (VEGF and IL-8). Moreover, selective targeting of the host (mouse) TF reveals its independent role in glioma tumorigenesis. We propose that TF may represent an attractive potential target to treat human brain tumors.

No description available.

Das Glioblastoma multiforme (GBM) ist der am häufigsten vorkommende maligne Hirntumor mit äußerst ungünstiger Prognose für die betroffenen Patienten. Typisch für die Tumore ist eine hohe Aktivität der Glykolyse zur Generierung von ATP und zur Bereitstellung von Makromolekülen für die Zellproliferation, während die oxidative Phosphorylierung auch in Gegenwart von Sauerstoff praktisch keine Bedeutung für die Generation von ATP hat, was auch als Warburg Effekt bekannt ist. Das natürlich vorkommende Carnosin (β-Alanyl-LHistidin) wirkt sich antiproliferativ auf Tumorzellen aus, was mit einer Inhibition der glykolytischen ATP Produktion einhergeht. Der Mechanismus der Inhibition ist weitgehend unverstanden und ist Gegenstand der vorliegenden Arbeit. Im Rahmen der durchgeführten Arbeit wurde der Einfluss von Carnosin auf die mRNA Expressionen von für die Glykolyse relevanten Genen untersucht, wobei eine starke Induktion der Pyruvatdehydrogenase Kinase (PDK) 4 in drei GBM Zelllinien beobachtet wurde. Weiterhin konnte gezeigt werden, dass L-Histidin den gleichen Effekt wie Carnosin zeigt, nicht jedoch β-Alanin, L-Alanin oder L-Alanyl-L-Histidin. Da Tumorzellen die intrazelluläre Gewebscarnosinase aber kaum die extrazelluläre Serumcarnosinase exprimieren, liegt die Vermutung nahe, dass die antineoplastische Wirkung des Carnosins auf die enzymatische Spaltung von Carnosin und die daraus resultierende Freisetzung von L-Histidin zurückzuführen ist. In weiteren Untersuchungen wurden Hinweise erbracht, dass Carnosin durch eine Beeinflussung von Histon-Deacetylasen, die endogene PDK4 mRNA Expression steigern könnte. Zusätzlich wurden die Proteinexpressionen der PDK1 und 4 unter dem Einfluss von Carnosin untersucht.

No description available.

This thesis addresses the challenge of prognosis, in terms of survival prediction, for patients with Glioblastoma Multiforme brain tumors. Glioblastoma is the most malignant brain tumor, which has a median survival time of no more than a year. Accurate assessment of prognostic factors is critical in deciding amongst different treatment options and in designing stratified clinical trials. This thesis is motivated by two observations. Firstly, clinicians often refer to properties of glioblastoma tumors based on magnetic resonance images when assessing prognosis. However, clinical data, along with histological and most recently, molecular and gene expression data, have been more widely and systematically studied and used in prognosis assessment than image based information. Secondly, patient survival times are often used along with clinical data to conduct population studies on brain tumor patients. Recursive Partitioning Analysis is typically used in these population studies. However, researchers validate and assess the predictive power of these models by measuring the statistical association between survival groups and survival times. In this thesis, we propose a learning approach that uses historical training data to produce a system that predicts patient survival. We introduce a classification model for predicting patient survival class, which uses texture based features extracted from magnetic resonance images as well as other patient properties. Our prognosis approach is novel as it is the first to use image-extracted textural characteristics of glioblastoma scans, in a classification model whose accuracy can be reliably validated by cross validation. We show that our approach is a promising new direction for prognosis in brain tumor patients.

Despite recent advances in oncology and extensive research efforts, gliomas remain essentially incurable. Glioblastoma multiforme (GBM, WHO grade IV) is the most common glioma and may arise de novo or progress from a lower-grade lesion. GBM is characterized by invasive growth, aberrant angiogenesis and necrosis. The heterogeneity of GBM is further complicated by the contribution of the inflammation that is facilitated by immune cells that reside in and infiltrate this immuno-privileged organ. One of the cells types present in the tumor microenvironment are mast cells (MC) that accumulate in the tumor in a grade-dependent manner. GBM cells secrete a plethora of cytokines acting as chemoattractants in MC recruitment and to a lesser degree induce MC proliferation in situ. Expression of one of the cytokines secreted by GBM cells - macrophage migration inhibitory factor (MIF) - correlates with MC accumulation in vivo. GBM cells invade the surrounding parenchyma making complete resection impossible. Here, migration was studied with the focus on RAP1 and its negative regulator RAP1GAP. Activation of RAP1 signaling by lentiviral silencing of RAP1GAP lead to decrease in cell migration and a shift in expression of SOX2 and GFAP, presumably enhancing stem cell phenotype. MicroRNAs are small non-coding RNAs known to regulate the mRNA network. miR-21 is highly overexpressed in the majority of cancers including GBM. Its expression is strictly regulated during embryonic development of the brain. SOX2 is co-regulated with miR-21 demarcating a cell population with neural/glial progenitor/stem cell properties. In an experimental mouse model, expression of miR-21 can be sustained by forced expression of PDGF-BB leading to gliomagenesis. GBM cells seem to be addicted to oncogenic properties of miR-21 as its knockdown leads to extensive apoptosis. This observation combined with the fact that miR-21 is absent in the normal adult mammalian brain suggest miR-21 to be an excellent therapeutic target. Effects of conventional therapy (surgery combined with radiochemotherapy) on prolonging patient survival have reached a plateau. New effective personalized therapeutic modalities need to be designed and implemented. Targeting the tumor microenvironment as well as cell intrinsic properties like invasive potential, stemness and onco-miR addiction studied in this thesis will hopefully lead to efficient disruption of GBM’s aberrant ecosystem.

Gliomas are the commonest primary tumours of the brain and glioblastoma multiforme (GBM) represents more than 50% of this group. GBM remains a neurosurgical conundrum since patients often succumb to the disease within one year. Surgery followed by radiation and medical regimens over the years have had minimal impact on the prognosis of patients with this cancer and hence, alternative and novel therapeutic modalities are required if the survival of patients with this disease is to be significantly improved. The ATM gene, which is mutated in the disease ataxia-telangiectasia (A-T), is implicated in response to radiation-induced DNA damage, leading to profound radiosensitivity. By reducing the levels of ATM in the radioresistant GBM cells through antisense or RNA interference (RNAi) technology delivered by lentiviruses, malignant GBM tumour cells were successfully sensitised to radiation treatment. In conjunction with surgery, this strategy will provide an enhanced therapeutic intervention especially in the case of GBM where the tumour is untreatable. In this thesis, analysis of the D-3-Phosphoglycerate dehydrogenase promoter in a GBM cell line as well as the development of a novel rat model for GBM using a bioluminescent F98 cell line will also be presented.

Thesis (M.A.) -- University of Texas Southwestern Medical Center at Dallas, 2004. / Vita. Bibliography: 93-98.

Thesis (M.S.)--Northern Michigan University, 2008. / "14-57395." Bibliography: leaves 41-42.